Clinical Leader Solutions Expo: Early-Phase Oncology Trials (CRO)

Oncology has been and continues to be the leading priority in global drug development. 44% of all Phase I-III trials, current and planned, are tackling oncology. But as the push to combat cancer evolves, so too has the drug development arena. In the last decade, small and emerging biopharma has surged to the forefront of oncology development, comprising 70% of 2023 trial starts according to IQVIA Institute. With young, innovative, funding-conscious companies leading the charge, experienced trial partners are pivotal to commercial and patient success.

The Clinical Leader Solutions Expo: Early Phase Oncology CROs brings an array of industry leaders and niche experts from CROs adept in guiding small and emerging biopharma through these complex trials. Designed with input from biotech teams, this event goes beyond basic pitches to highlight the key differentiators of each presenting partner in an interactive forum built for teams just starting to explore CRO services, to those who are ready for conversations.